RMP Lifecycle Management Knowledge Assessment

To replace all trigger-driven reviews To reconcile the RMP with current safety databases, PSUR/PBRER conclusions, and ongoing studies To confirm that no RMP changes can be made between annual cycles To review only the formatting and pagination of the RMP

Update only the product name and indication in the administrative section Wait until a paediatric adverse reaction is reported before reviewing the RMP Systematically reassess the safety specification, pharmacovigilance activities, risk minimisation, and relevant local annexes Replace the existing RMP with the paediatric study protocol

Handle it through the standard timeline without escalation to preserve consistency Defer action until the next scheduled RMP health-check Use an expedited pathway with defined shortened timelines and emergency governance arrangements Wait for publication of additional literature before assessing the request

Regulatory submission, signal detection, approval, then scientific assessment Signal or data source, documented assessment, RMP decision, approval, and supporting implementation records RMP revision, informal discussion, signal confirmation, and archive of the original evidence Risk minimisation implementation, signal detection, and retrospective preparation of the rationale

It is updated only when the marketing authorisation is renewed It is continuously reviewed and revised when new evidence affects the risk-management strategy It is replaced by the latest PSUR once sufficient post-marketing data are available It remains unchanged after approval unless an inspector requests a revision

To replace the scientific rationale for an RMP update To provide a traceable record of versions, triggers, changes, approvals, evidence, and regulatory outcomes To record only the dates on which the RMP was submitted To document commercial decisions about product positioning

An unsigned draft containing tracked changes A final approved RMP without evidence of review Reviewer comments, governance minutes where applicable, final approval records, and delegation records if relevant A verbal confirmation from the product team

Whether the information produces a statistically significant change in reporting frequency Whether the information affects ongoing risk management Whether the information has already been published in a peer-reviewed journal Whether the information concerns a serious adverse reaction in at least one patient

The topic has not generated recent spontaneous reports The concern has been present in the RMP for more than five years Registry data sufficiently resolve the uncertainty and support discontinuing the related activity without compromising public health The registry was difficult to manage and exceeded its budget

Only the study budget and anticipated publication date Objectives, timelines, success criteria, and decision points Only the number of patients to be enrolled A commitment to continue the activity for the entire product lifecycle